Last edition
News about "Tony Wood"
GSK will acquire RAPT Therapeutics for USD 2.2 billion, adding phase IIb anti-IgE antibody ozureprubart to its pipeline, targeting long-acting protection for patients with severe food allergies.
Tony Wood | 20/01/2026 | By News Bureau | 167
Hengrui Pharma has signed agreements with GSK to develop up to 12 innovative medicines across respiratory, immunology and inflammation, and oncology. It includes license for potential best-in-class PDE3/4 inhibitor (HRS-9821) in clinical development for treatment of COPD and additional 11 programmes to be developed by Hengrui Pharma and optioned by GSK.
Tony Wood | 28/07/2025 | By Mrinmoy Dey | 283
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy